Levodropropizine
As of the edition of 20 October 2026, Levodropropizine is a small molecule: marketed, first approved in 1997 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Angituss
- First approved
- 1 April 1997 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Gebro Pharma; 2 holders in all
- Registered trials
- 6, 0 stopped early
- Disease areas
- Lungs and airways; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gebro Pharma | Applicant | 2024 to now |